Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “V-Immune will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose”In the company’s words, NCT07017036 on ClinicalTrials.gov
- Tested for
- Primary Immunodeficiency Diseases (PID)
- Main trialPhase 3
- “The study duration for individual patients will be up to 55 weeks for the 4-weekly and 3- weekly schedule of the treatment which includes 3 weeks for screening, 48 weeks for Study Medication administration and 4 weeks for follow-up assessments”In the company’s words, NCT07017036 on ClinicalTrials.gov
Other drugs for Primary Immunodeficiency Diseases (PID)
- PanzygaOctapharma · Phase 3
- DonidalorsenIonis Pharmaceuticals, Inc. · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- NavenibartAstria Therapeutics, Inc. · Phase 3
- DeucrictibantPharvaris Netherlands B.V. · Phase 3
- ADX-324ADARx Pharmaceuticals, Inc. · Phase 3
Coming up1
- 1 DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 1 Dec 2026 | Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026